Nephrin Loss Can Be Used to Predict Remission and Long-term Renal Outcome in Patients With Minimal Change Disease.
Introduction
Minimal change disease is a common cause of nephrotic syndrome. In general, patients with minimal change disease respond to corticosteroids and have excellent long-term renal survival. However, some patients have less favorable outcome. These patients are often thought to have progressed to focal segmental glomerulosclerosis. We previously reported that a segmental loss of podocyte markers is present before the development of focal segmental glomerulosclerosis in a rat model. Here, we investigated whether loss of podocyte marker nephrin can serve as a biomarker for predicting poor outcome in patients with minimal change disease.


Methods
We obtained 47 kidney biopsy samples from patients diagnosed with minimal change disease and stained sections with periodic acid-Schiff and for nephrin. Nephrin loss was scored by 2 independent researchers who were blinded to clinical outcome. Clinical data were collected retrospectively, and nephrin loss was correlated with clinical follow-up data.


Results
Nephrin loss was present in 34% of the biopsy samples. During follow-up, patients with nephrin loss achieved remission less frequently (61%) compared to patients without (96%) (P = 0.002). Moreover, 5-year eGFR was lower in the patients with renal nephrin loss. The risk of eGFR decreasing to < 60 ml/min per 1.73m2 increased with each percentage of glomeruli with nephrin loss (hazard ratio = 1.044, 95% confidence interval = 1.02-1.07).


Conclusion
These results indicate that nephrin loss in patients with minimal change disease can help predict both remission and long-term renal outcome.
['van de Lest|Nina A|NA|', 'Zandbergen|Malu|M|', 'IJpelaar|Daphne H T|DHT|', 'Wolterbeek|Ron|R|', 'Bruijn|Jan A|JA|', 'Bajema|Ingeborg M|IM|', 'Scharpfenecker|Marion|M|']
nephrin minimal change disease nephrotic syndrome focal segmental glomerulosclerosis biomarker